Texas Capital Bancshares diskutieren
Texas Capital Bancshares
WKN: 121221 / Symbol: TCBI / Name: Texas Capital / Aktie / Banken / Mid Cap /
82,00 €
-0,61 %
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "buy" rating. They now have a $77.00 price target on the stock, up previously from $51.00.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its "outperform" rating re-affirmed by analysts at Keefe, Bruyette & Woods. They now have a $74.00 price target on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $73.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) was upgraded by analysts at Raymond James from a "market perform" rating to an "outperform" rating. They now have a $78.00 price target on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at JPMorgan Chase & Co. from $73.00 to $72.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target raised by analysts at Barclays PLC from $49.00 to $60.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $80.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its "underperform" rating re-affirmed by analysts at Truist Financial Co..
Ratings data for TCBI provided by MarketBeat
Hey there, fellow investors! I've been eyeing Texas Capital Bancshares lately, and I've got to say, I'm pretty impressed. This stock's been on a roll, showing some serious momentum that's hard to ignore. Think of it like a snowball rolling downhill - it's picking up speed and getting bigger by the minute!
First off, their Q3 earnings were a pleasant surprise. They smashed expectations with earnings of $1.62 per share, way above the $0.97 estimate. That's like finding an extra slice of pizza in the box when you thought you'd finished the whole thing!
What's really catching my eye is their fee income growth. They hit a record high in Q3, with non-interest income jumping 38% year-over-year. That's diversification in action, folks - not putting all their eggs in the interest income basket.
Sure, there are a few wrinkles. Their commercial real estate portfolio saw some payoffs, and there's a slight increase in criticized loans. But hey, no rose without thorns, right?
Looking ahead, I'm optimistic. Their focus on middle-market businesses and high-net-worth individuals in Texas's booming cities seems like a smart play. It's like they've set up shop at the busiest intersection in town - plenty of traffic coming their way.
With their strong capital position and strategic initiatives, I think TCBI's got more gas in the tank. The current price of $70.5 feels like a bargain for a bank that's firing on all cylinders. I'm targeting $80.5 as a reasonable goal, given their growth trajectory and market position.
Remember, though, the market's as unpredictable as Texas weather. Do your own digging before making any moves!
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target raised by analysts at Barclays PLC from $60.00 to $71.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at JPMorgan Chase & Co. from $86.00 to $81.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at JPMorgan Chase & Co. from $81.00 to $80.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at Stephens from $102.00 to $97.00. They now have an "overweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its "outperform" rating re-affirmed by analysts at Keefe, Bruyette & Woods. They now have a $95.00 price target on the stock, down previously from $100.00.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at Barclays PLC from $73.00 to $70.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at Raymond James from $87.00 to $80.00. They now have an "outperform" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at Stephens from $95.00 to $90.00. They now have an "overweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at Keefe, Bruyette & Woods from $92.00 to $86.00. They now have an "outperform" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $70.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat
Texas Capital Bancshares, Inc. (NASDAQ: TCBI) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $82.00. They now have an "underweight" rating on the stock.
Ratings data for TCBI provided by MarketBeat



Neueste Beiträge
Wells_Fargo___Compan in Johnson & Johnson diskutieren